Acerta Pharma B.v.

Oncternal Therapeutics, Inc.

Gilead Calistoga LLC

Velosbio Inc.

Acera Pharma B.v.

Brian Lannutti

Wayne Philip Rothbaum

Allard Kaptein

Roger G Ulrich

Tjeerd Barf

Raquel Izumi

Ahmed Hamdy

Todd Covey

Dave Johnson

Katayoun Jessen

James Bradley Breitmeyer

Neill A Giese

Jeffry Dean Watkins

W Michael Gallatin

Langdon Miller

Katti Jessen

Thanh-Trang Vo

Thomas M Jahn

Jerry B Evarts

Kamal Deep Puri

David M Johnson

Roger Ulrich

Provided herein are immunoconjugates comprising an anti-ROR-1 antibody or an antigen-fragmentfragmentthereof and a drug moiety. These immunoconjugates are useful for treating ROR-1 expressing cancers.

ROR1 antibody immunoconjugates

Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.

Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor

Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.

Uses of indolinone compounds

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the &#x3b3;- and &#x3b4;-isoforms and selective for both &#x3b3;- and &#x3b4;-isoforms (PI3K-&#x3b3;,&#x3b4;, PI3K-&#x3b3;, and PI3K-&#x3b4;), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-&#x3b4; inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor

Therapeutic combinations of a MEK inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a MEK inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

Therapeutic combinations of a MEK inhibitor and a BTK inhibitor

Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the &#x3b3;- and &#x3b4;-isoforms and selective for both &#x3b3;- and &#x3b4;-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor. In some embodiments, the invention includes therapeutic methods of using a BTK inhibitor and a PI3K-&#x3b4; inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

Therapeutic combination of PI3K inhibitor and a BTK inhibitor

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, 

Therapies for hematologic malignancies

Growing community of inventors

Solana Beach, CA, United States of America

Brian Lannutti